世界の軽度認知障害(MCI)治療市場インサイト及び予測(~2026年)

【英語タイトル】Global Mild Cognitive Impairment Therapeutic Market Size, Status and Forecast 2020-2026

QYResearchが出版した調査資料(QYR20NV12693)・商品コード:QYR20NV12693
・発行会社(調査会社):QYResearch
・発行日:2020年11月
・ページ数:126
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥421,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥631,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥842,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートは軽度認知障害(MCI)治療の世界市場について調査・分析した資料です。種類別(BAN-2401、ボスチニブ、ブレキサノロン、CSP-1103、その他)の市場規模、用途別(病院、クリニック、その他)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別軽度認知障害(MCI)治療の競争状況、市場シェア
・世界の軽度認知障害(MCI)治療市場:種類別市場規模 2015年-2020年(BAN-2401、ボスチニブ、ブレキサノロン、CSP-1103、その他)
・世界の軽度認知障害(MCI)治療市場:種類別市場規模予測 2021年-2026年(BAN-2401、ボスチニブ、ブレキサノロン、CSP-1103、その他)
・世界の軽度認知障害(MCI)治療市場:用途別市場規模 2015年-2020年(病院、クリニック、その他)
・世界の軽度認知障害(MCI)治療市場:用途別市場規模予測 2021年-2026年(病院、クリニック、その他)
・北米の軽度認知障害(MCI)治療市場分析:米国、カナダ
・ヨーロッパの軽度認知障害(MCI)治療市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの軽度認知障害(MCI)治療市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の軽度認知障害(MCI)治療市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの軽度認知障害(MCI)治療市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):AgeneBio Inc、Avraham Pharmaceuticals Ltd、CereSpir Inc、ConSynance Therapeutics Inc、Eisai Co Ltd、Eli Lilly and Company、Ensol Biosciences Inc、Genzyme Corp、IntelGenx Corp、Krenitsky Pharmaceuticals Inc、Merck & Co Inc、Nanotherapeutics Inc、Neuron Biopharma SA、Pfizer Inc、Sage Therapeutics Inc、SBI Pharmaceuticals Co Ltd、Suven Life Sciences Ltd、Takeda Pharmaceutical Company Ltd、Therapix Biosciences Ltd
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Market Analysis and Insights: Global Mild Cognitive Impairment Therapeutic Market
The global Mild Cognitive Impairment Therapeutic market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Mild Cognitive Impairment Therapeutic Scope and Market Size
Mild Cognitive Impairment Therapeutic market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Mild Cognitive Impairment Therapeutic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
AgeneBio Inc
Avraham Pharmaceuticals Ltd
CereSpir Inc
ConSynance Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Company
Ensol Biosciences Inc
Genzyme Corp
IntelGenx Corp
Krenitsky Pharmaceuticals Inc
Merck & Co Inc
Nanotherapeutics Inc
Neuron Biopharma SA
Pfizer Inc
Sage Therapeutics Inc
SBI Pharmaceuticals Co Ltd
Suven Life Sciences Ltd
Takeda Pharmaceutical Company Ltd
Therapix Biosciences Ltd

Market segment by Type, the product can be split into
BAN-2401
Bosutinib
Brexanolone
CSP-1103
Others
Market segment by Application, split into
Hospital
Clinic
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Mild Cognitive Impairment Therapeutic Revenue
1.4 Market by Type
1.4.1 Global Mild Cognitive Impairment Therapeutic Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 BAN-2401
1.4.3 Bosutinib
1.4.4 Brexanolone
1.4.5 CSP-1103
1.4.6 Others
1.5 Market by Application
1.5.1 Global Mild Cognitive Impairment Therapeutic Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Mild Cognitive Impairment Therapeutic Market Perspective (2015-2026)
2.2 Global Mild Cognitive Impairment Therapeutic Growth Trends by Regions
2.2.1 Mild Cognitive Impairment Therapeutic Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Mild Cognitive Impairment Therapeutic Historic Market Share by Regions (2015-2020)
2.2.3 Mild Cognitive Impairment Therapeutic Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Mild Cognitive Impairment Therapeutic Market Growth Strategy
2.3.6 Primary Interviews with Key Mild Cognitive Impairment Therapeutic Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Mild Cognitive Impairment Therapeutic Players by Market Size
3.1.1 Global Top Mild Cognitive Impairment Therapeutic Players by Revenue (2015-2020)
3.1.2 Global Mild Cognitive Impairment Therapeutic Revenue Market Share by Players (2015-2020)
3.1.3 Global Mild Cognitive Impairment Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Mild Cognitive Impairment Therapeutic Market Concentration Ratio
3.2.1 Global Mild Cognitive Impairment Therapeutic Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Mild Cognitive Impairment Therapeutic Revenue in 2019
3.3 Mild Cognitive Impairment Therapeutic Key Players Head office and Area Served
3.4 Key Players Mild Cognitive Impairment Therapeutic Product Solution and Service
3.5 Date of Enter into Mild Cognitive Impairment Therapeutic Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Mild Cognitive Impairment Therapeutic Historic Market Size by Type (2015-2020)
4.2 Global Mild Cognitive Impairment Therapeutic Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Mild Cognitive Impairment Therapeutic Market Size by Application (2015-2020)
5.2 Global Mild Cognitive Impairment Therapeutic Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Mild Cognitive Impairment Therapeutic Market Size (2015-2020)
6.2 Mild Cognitive Impairment Therapeutic Key Players in North America (2019-2020)
6.3 North America Mild Cognitive Impairment Therapeutic Market Size by Type (2015-2020)
6.4 North America Mild Cognitive Impairment Therapeutic Market Size by Application (2015-2020)

7 Europe
7.1 Europe Mild Cognitive Impairment Therapeutic Market Size (2015-2020)
7.2 Mild Cognitive Impairment Therapeutic Key Players in Europe (2019-2020)
7.3 Europe Mild Cognitive Impairment Therapeutic Market Size by Type (2015-2020)
7.4 Europe Mild Cognitive Impairment Therapeutic Market Size by Application (2015-2020)

8 China
8.1 China Mild Cognitive Impairment Therapeutic Market Size (2015-2020)
8.2 Mild Cognitive Impairment Therapeutic Key Players in China (2019-2020)
8.3 China Mild Cognitive Impairment Therapeutic Market Size by Type (2015-2020)
8.4 China Mild Cognitive Impairment Therapeutic Market Size by Application (2015-2020)

9 Japan
9.1 Japan Mild Cognitive Impairment Therapeutic Market Size (2015-2020)
9.2 Mild Cognitive Impairment Therapeutic Key Players in Japan (2019-2020)
9.3 Japan Mild Cognitive Impairment Therapeutic Market Size by Type (2015-2020)
9.4 Japan Mild Cognitive Impairment Therapeutic Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Mild Cognitive Impairment Therapeutic Market Size (2015-2020)
10.2 Mild Cognitive Impairment Therapeutic Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Mild Cognitive Impairment Therapeutic Market Size by Type (2015-2020)
10.4 Southeast Asia Mild Cognitive Impairment Therapeutic Market Size by Application (2015-2020)

11 India
11.1 India Mild Cognitive Impairment Therapeutic Market Size (2015-2020)
11.2 Mild Cognitive Impairment Therapeutic Key Players in India (2019-2020)
11.3 India Mild Cognitive Impairment Therapeutic Market Size by Type (2015-2020)
11.4 India Mild Cognitive Impairment Therapeutic Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Mild Cognitive Impairment Therapeutic Market Size (2015-2020)
12.2 Mild Cognitive Impairment Therapeutic Key Players in Central & South America (2019-2020)
12.3 Central & South America Mild Cognitive Impairment Therapeutic Market Size by Type (2015-2020)
12.4 Central & South America Mild Cognitive Impairment Therapeutic Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 AgeneBio Inc
13.1.1 AgeneBio Inc Company Details
13.1.2 AgeneBio Inc Business Overview
13.1.3 AgeneBio Inc Mild Cognitive Impairment Therapeutic Introduction
13.1.4 AgeneBio Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020))
13.1.5 AgeneBio Inc Recent Development
13.2 Avraham Pharmaceuticals Ltd
13.2.1 Avraham Pharmaceuticals Ltd Company Details
13.2.2 Avraham Pharmaceuticals Ltd Business Overview
13.2.3 Avraham Pharmaceuticals Ltd Mild Cognitive Impairment Therapeutic Introduction
13.2.4 Avraham Pharmaceuticals Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020)
13.2.5 Avraham Pharmaceuticals Ltd Recent Development
13.3 CereSpir Inc
13.3.1 CereSpir Inc Company Details
13.3.2 CereSpir Inc Business Overview
13.3.3 CereSpir Inc Mild Cognitive Impairment Therapeutic Introduction
13.3.4 CereSpir Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020)
13.3.5 CereSpir Inc Recent Development
13.4 ConSynance Therapeutics Inc
13.4.1 ConSynance Therapeutics Inc Company Details
13.4.2 ConSynance Therapeutics Inc Business Overview
13.4.3 ConSynance Therapeutics Inc Mild Cognitive Impairment Therapeutic Introduction
13.4.4 ConSynance Therapeutics Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020)
13.4.5 ConSynance Therapeutics Inc Recent Development
13.5 Eisai Co Ltd
13.5.1 Eisai Co Ltd Company Details
13.5.2 Eisai Co Ltd Business Overview
13.5.3 Eisai Co Ltd Mild Cognitive Impairment Therapeutic Introduction
13.5.4 Eisai Co Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020)
13.5.5 Eisai Co Ltd Recent Development
13.6 Eli Lilly and Company
13.6.1 Eli Lilly and Company Company Details
13.6.2 Eli Lilly and Company Business Overview
13.6.3 Eli Lilly and Company Mild Cognitive Impairment Therapeutic Introduction
13.6.4 Eli Lilly and Company Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020)
13.6.5 Eli Lilly and Company Recent Development
13.7 Ensol Biosciences Inc
13.7.1 Ensol Biosciences Inc Company Details
13.7.2 Ensol Biosciences Inc Business Overview
13.7.3 Ensol Biosciences Inc Mild Cognitive Impairment Therapeutic Introduction
13.7.4 Ensol Biosciences Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020)
13.7.5 Ensol Biosciences Inc Recent Development
13.8 Genzyme Corp
13.8.1 Genzyme Corp Company Details
13.8.2 Genzyme Corp Business Overview
13.8.3 Genzyme Corp Mild Cognitive Impairment Therapeutic Introduction
13.8.4 Genzyme Corp Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020)
13.8.5 Genzyme Corp Recent Development
13.9 IntelGenx Corp
13.9.1 IntelGenx Corp Company Details
13.9.2 IntelGenx Corp Business Overview
13.9.3 IntelGenx Corp Mild Cognitive Impairment Therapeutic Introduction
13.9.4 IntelGenx Corp Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020)
13.9.5 IntelGenx Corp Recent Development
13.10 Krenitsky Pharmaceuticals Inc
13.10.1 Krenitsky Pharmaceuticals Inc Company Details
13.10.2 Krenitsky Pharmaceuticals Inc Business Overview
13.10.3 Krenitsky Pharmaceuticals Inc Mild Cognitive Impairment Therapeutic Introduction
13.10.4 Krenitsky Pharmaceuticals Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020)
13.10.5 Krenitsky Pharmaceuticals Inc Recent Development
13.11 Merck & Co Inc
10.11.1 Merck & Co Inc Company Details
10.11.2 Merck & Co Inc Business Overview
10.11.3 Merck & Co Inc Mild Cognitive Impairment Therapeutic Introduction
10.11.4 Merck & Co Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020)
10.11.5 Merck & Co Inc Recent Development
13.12 Nanotherapeutics Inc
10.12.1 Nanotherapeutics Inc Company Details
10.12.2 Nanotherapeutics Inc Business Overview
10.12.3 Nanotherapeutics Inc Mild Cognitive Impairment Therapeutic Introduction
10.12.4 Nanotherapeutics Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020)
10.12.5 Nanotherapeutics Inc Recent Development
13.13 Neuron Biopharma SA
10.13.1 Neuron Biopharma SA Company Details
10.13.2 Neuron Biopharma SA Business Overview
10.13.3 Neuron Biopharma SA Mild Cognitive Impairment Therapeutic Introduction
10.13.4 Neuron Biopharma SA Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020)
10.13.5 Neuron Biopharma SA Recent Development
13.14 Pfizer Inc
10.14.1 Pfizer Inc Company Details
10.14.2 Pfizer Inc Business Overview
10.14.3 Pfizer Inc Mild Cognitive Impairment Therapeutic Introduction
10.14.4 Pfizer Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020)
10.14.5 Pfizer Inc Recent Development
13.15 Sage Therapeutics Inc
10.15.1 Sage Therapeutics Inc Company Details
10.15.2 Sage Therapeutics Inc Business Overview
10.15.3 Sage Therapeutics Inc Mild Cognitive Impairment Therapeutic Introduction
10.15.4 Sage Therapeutics Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020)
10.15.5 Sage Therapeutics Inc Recent Development
13.16 SBI Pharmaceuticals Co Ltd
10.16.1 SBI Pharmaceuticals Co Ltd Company Details
10.16.2 SBI Pharmaceuticals Co Ltd Business Overview
10.16.3 SBI Pharmaceuticals Co Ltd Mild Cognitive Impairment Therapeutic Introduction
10.16.4 SBI Pharmaceuticals Co Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020)
10.16.5 SBI Pharmaceuticals Co Ltd Recent Development
13.17 Suven Life Sciences Ltd
10.17.1 Suven Life Sciences Ltd Company Details
10.17.2 Suven Life Sciences Ltd Business Overview
10.17.3 Suven Life Sciences Ltd Mild Cognitive Impairment Therapeutic Introduction
10.17.4 Suven Life Sciences Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020)
10.17.5 Suven Life Sciences Ltd Recent Development
13.18 Takeda Pharmaceutical Company Ltd
10.18.1 Takeda Pharmaceutical Company Ltd Company Details
10.18.2 Takeda Pharmaceutical Company Ltd Business Overview
10.18.3 Takeda Pharmaceutical Company Ltd Mild Cognitive Impairment Therapeutic Introduction
10.18.4 Takeda Pharmaceutical Company Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020)
10.18.5 Takeda Pharmaceutical Company Ltd Recent Development
13.19 Therapix Biosciences Ltd
10.19.1 Therapix Biosciences Ltd Company Details
10.19.2 Therapix Biosciences Ltd Business Overview
10.19.3 Therapix Biosciences Ltd Mild Cognitive Impairment Therapeutic Introduction
10.19.4 Therapix Biosciences Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020)
10.19.5 Therapix Biosciences Ltd Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Mild Cognitive Impairment Therapeutic Key Market Segments
Table 2. Key Players Covered: Ranking by Mild Cognitive Impairment Therapeutic Revenue
Table 3. Ranking of Global Top Mild Cognitive Impairment Therapeutic Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Mild Cognitive Impairment Therapeutic Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of BAN-2401
Table 6. Key Players of Bosutinib
Table 7. Key Players of Brexanolone
Table 8. Key Players of CSP-1103
Table 9. Key Players of Others
Table 10. Global Mild Cognitive Impairment Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Mild Cognitive Impairment Therapeutic Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Mild Cognitive Impairment Therapeutic Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Mild Cognitive Impairment Therapeutic Market Share by Regions (2015-2020)
Table 14. Global Mild Cognitive Impairment Therapeutic Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Mild Cognitive Impairment Therapeutic Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Mild Cognitive Impairment Therapeutic Market Growth Strategy
Table 20. Main Points Interviewed from Key Mild Cognitive Impairment Therapeutic Players
Table 21. Global Mild Cognitive Impairment Therapeutic Revenue by Players (2015-2020) (Million US$)
Table 22. Global Mild Cognitive Impairment Therapeutic Market Share by Players (2015-2020)
Table 23. Global Top Mild Cognitive Impairment Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Mild Cognitive Impairment Therapeutic as of 2019)
Table 24. Global Mild Cognitive Impairment Therapeutic by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Mild Cognitive Impairment Therapeutic Product Solution and Service
Table 27. Date of Enter into Mild Cognitive Impairment Therapeutic Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Mild Cognitive Impairment Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 30. Global Mild Cognitive Impairment Therapeutic Market Size Share by Type (2015-2020)
Table 31. Global Mild Cognitive Impairment Therapeutic Revenue Market Share by Type (2021-2026)
Table 32. Global Mild Cognitive Impairment Therapeutic Market Size Share by Application (2015-2020)
Table 33. Global Mild Cognitive Impairment Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 34. Global Mild Cognitive Impairment Therapeutic Market Size Share by Application (2021-2026)
Table 35. North America Key Players Mild Cognitive Impairment Therapeutic Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Mild Cognitive Impairment Therapeutic Market Share (2019-2020)
Table 37. North America Mild Cognitive Impairment Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 38. North America Mild Cognitive Impairment Therapeutic Market Share by Type (2015-2020)
Table 39. North America Mild Cognitive Impairment Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 40. North America Mild Cognitive Impairment Therapeutic Market Share by Application (2015-2020)
Table 41. Europe Key Players Mild Cognitive Impairment Therapeutic Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Mild Cognitive Impairment Therapeutic Market Share (2019-2020)
Table 43. Europe Mild Cognitive Impairment Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Mild Cognitive Impairment Therapeutic Market Share by Type (2015-2020)
Table 45. Europe Mild Cognitive Impairment Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Mild Cognitive Impairment Therapeutic Market Share by Application (2015-2020)
Table 47. China Key Players Mild Cognitive Impairment Therapeutic Revenue (2019-2020) (Million US$)
Table 48. China Key Players Mild Cognitive Impairment Therapeutic Market Share (2019-2020)
Table 49. China Mild Cognitive Impairment Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 50. China Mild Cognitive Impairment Therapeutic Market Share by Type (2015-2020)
Table 51. China Mild Cognitive Impairment Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 52. China Mild Cognitive Impairment Therapeutic Market Share by Application (2015-2020)
Table 53. Japan Key Players Mild Cognitive Impairment Therapeutic Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Mild Cognitive Impairment Therapeutic Market Share (2019-2020)
Table 55. Japan Mild Cognitive Impairment Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Mild Cognitive Impairment Therapeutic Market Share by Type (2015-2020)
Table 57. Japan Mild Cognitive Impairment Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Mild Cognitive Impairment Therapeutic Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Mild Cognitive Impairment Therapeutic Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Mild Cognitive Impairment Therapeutic Market Share (2019-2020)
Table 61. Southeast Asia Mild Cognitive Impairment Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Mild Cognitive Impairment Therapeutic Market Share by Type (2015-2020)
Table 63. Southeast Asia Mild Cognitive Impairment Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Mild Cognitive Impairment Therapeutic Market Share by Application (2015-2020)
Table 65. India Key Players Mild Cognitive Impairment Therapeutic Revenue (2019-2020) (Million US$)
Table 66. India Key Players Mild Cognitive Impairment Therapeutic Market Share (2019-2020)
Table 67. India Mild Cognitive Impairment Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 68. India Mild Cognitive Impairment Therapeutic Market Share by Type (2015-2020)
Table 69. India Mild Cognitive Impairment Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 70. India Mild Cognitive Impairment Therapeutic Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Mild Cognitive Impairment Therapeutic Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Mild Cognitive Impairment Therapeutic Market Share (2019-2020)
Table 73. Central & South America Mild Cognitive Impairment Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Mild Cognitive Impairment Therapeutic Market Share by Type (2015-2020)
Table 75. Central & South America Mild Cognitive Impairment Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Mild Cognitive Impairment Therapeutic Market Share by Application (2015-2020)
Table 77. AgeneBio Inc Company Details
Table 78. AgeneBio Inc Business Overview
Table 79. AgeneBio Inc Product
Table 80. AgeneBio Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020) (Million US$)
Table 81. AgeneBio Inc Recent Development
Table 82. Avraham Pharmaceuticals Ltd Company Details
Table 83. Avraham Pharmaceuticals Ltd Business Overview
Table 84. Avraham Pharmaceuticals Ltd Product
Table 85. Avraham Pharmaceuticals Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020) (Million US$)
Table 86. Avraham Pharmaceuticals Ltd Recent Development
Table 87. CereSpir Inc Company Details
Table 88. CereSpir Inc Business Overview
Table 89. CereSpir Inc Product
Table 90. CereSpir Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020) (Million US$)
Table 91. CereSpir Inc Recent Development
Table 92. ConSynance Therapeutics Inc Company Details
Table 93. ConSynance Therapeutics Inc Business Overview
Table 94. ConSynance Therapeutics Inc Product
Table 95. ConSynance Therapeutics Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020) (Million US$)
Table 96. ConSynance Therapeutics Inc Recent Development
Table 97. Eisai Co Ltd Company Details
Table 98. Eisai Co Ltd Business Overview
Table 99. Eisai Co Ltd Product
Table 100. Eisai Co Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020) (Million US$)
Table 101. Eisai Co Ltd Recent Development
Table 102. Eli Lilly and Company Company Details
Table 103. Eli Lilly and Company Business Overview
Table 104. Eli Lilly and Company Product
Table 105. Eli Lilly and Company Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020) (Million US$)
Table 106. Eli Lilly and Company Recent Development
Table 107. Ensol Biosciences Inc Company Details
Table 108. Ensol Biosciences Inc Business Overview
Table 109. Ensol Biosciences Inc Product
Table 110. Ensol Biosciences Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020) (Million US$)
Table 111. Ensol Biosciences Inc Recent Development
Table 112. Genzyme Corp Business Overview
Table 113. Genzyme Corp Product
Table 114. Genzyme Corp Company Details
Table 115. Genzyme Corp Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020) (Million US$)
Table 116. Genzyme Corp Recent Development
Table 117. IntelGenx Corp Company Details
Table 118. IntelGenx Corp Business Overview
Table 119. IntelGenx Corp Product
Table 120. IntelGenx Corp Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020) (Million US$)
Table 121. IntelGenx Corp Recent Development
Table 122. Krenitsky Pharmaceuticals Inc Company Details
Table 123. Krenitsky Pharmaceuticals Inc Business Overview
Table 124. Krenitsky Pharmaceuticals Inc Product
Table 125. Krenitsky Pharmaceuticals Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020) (Million US$)
Table 126. Krenitsky Pharmaceuticals Inc Recent Development
Table 127. Merck & Co Inc Company Details
Table 128. Merck & Co Inc Business Overview
Table 129. Merck & Co Inc Product
Table 130. Merck & Co Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020) (Million US$)
Table 131. Merck & Co Inc Recent Development
Table 132. Nanotherapeutics Inc Company Details
Table 133. Nanotherapeutics Inc Business Overview
Table 134. Nanotherapeutics Inc Product
Table 135. Nanotherapeutics Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020) (Million US$)
Table 136. Nanotherapeutics Inc Recent Development
Table 137. Neuron Biopharma SA Company Details
Table 138. Neuron Biopharma SA Business Overview
Table 139. Neuron Biopharma SA Product
Table 140. Neuron Biopharma SA Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020) (Million US$)
Table 141. Neuron Biopharma SA Recent Development
Table 142. Pfizer Inc Company Details
Table 143. Pfizer Inc Business Overview
Table 144. Pfizer Inc Product
Table 145. Pfizer Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020) (Million US$)
Table 146. Pfizer Inc Recent Development
Table 147. Sage Therapeutics Inc Company Details
Table 148. Sage Therapeutics Inc Business Overview
Table 149. Sage Therapeutics Inc Product
Table 150. Sage Therapeutics Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020) (Million US$)
Table 151. Sage Therapeutics Inc Recent Development
Table 152. SBI Pharmaceuticals Co Ltd Company Details
Table 153. SBI Pharmaceuticals Co Ltd Business Overview
Table 154. SBI Pharmaceuticals Co Ltd Product
Table 155. SBI Pharmaceuticals Co Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020) (Million US$)
Table 156. SBI Pharmaceuticals Co Ltd Recent Development
Table 157. Suven Life Sciences Ltd Company Details
Table 158. Suven Life Sciences Ltd Business Overview
Table 159. Suven Life Sciences Ltd Product
Table 160. Suven Life Sciences Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020) (Million US$)
Table 161. Suven Life Sciences Ltd Recent Development
Table 162. Takeda Pharmaceutical Company Ltd Company Details
Table 163. Takeda Pharmaceutical Company Ltd Business Overview
Table 164. Takeda Pharmaceutical Company Ltd Product
Table 165. Takeda Pharmaceutical Company Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020) (Million US$)
Table 166. Takeda Pharmaceutical Company Ltd Recent Development
Table 167. Therapix Biosciences Ltd Company Details
Table 168. Therapix Biosciences Ltd Business Overview
Table 169. Therapix Biosciences Ltd Product
Table 170. Therapix Biosciences Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2015-2020) (Million US$)
Table 171. Therapix Biosciences Ltd Recent Development
Table 172. Research Programs/Design for This Report
Table 173. Key Data Information from Secondary Sources
Table 174. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Mild Cognitive Impairment Therapeutic Market Share by Type: 2020 VS 2026
Figure 2. BAN-2401 Features
Figure 3. Bosutinib Features
Figure 4. Brexanolone Features
Figure 5. CSP-1103 Features
Figure 6. Others Features
Figure 7. Global Mild Cognitive Impairment Therapeutic Market Share by Application: 2020 VS 2026
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Mild Cognitive Impairment Therapeutic Report Years Considered
Figure 12. Global Mild Cognitive Impairment Therapeutic Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Mild Cognitive Impairment Therapeutic Market Share by Regions: 2020 VS 2026
Figure 14. Global Mild Cognitive Impairment Therapeutic Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Mild Cognitive Impairment Therapeutic Market Share by Players in 2019
Figure 17. Global Top Mild Cognitive Impairment Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Mild Cognitive Impairment Therapeutic as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Mild Cognitive Impairment Therapeutic Revenue in 2019
Figure 19. North America Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed


【掲載企業】

AgeneBio Inc、Avraham Pharmaceuticals Ltd、CereSpir Inc、ConSynance Therapeutics Inc、Eisai Co Ltd、Eli Lilly and Company、Ensol Biosciences Inc、Genzyme Corp、IntelGenx Corp、Krenitsky Pharmaceuticals Inc、Merck & Co Inc、Nanotherapeutics Inc、Neuron Biopharma SA、Pfizer Inc、Sage Therapeutics Inc、SBI Pharmaceuticals Co Ltd、Suven Life Sciences Ltd、Takeda Pharmaceutical Company Ltd、Therapix Biosciences Ltd

★調査レポート[世界の軽度認知障害(MCI)治療市場インサイト及び予測(~2026年)] (コード:QYR20NV12693)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の軽度認知障害(MCI)治療市場インサイト及び予測(~2026年)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆